Stocks of the Hour: Telix Pharmaceuticals, AVITA Medical, EZZ Life Science
Stocks of the Hour: Telix Pharmaceuticals, AVITA Medical, EZZ Life Science
To register for today's webinar click here.
要注册今天的网络研讨会，请单击此处。
Telix Pharmaceuticals (ASX:TLX) announces additional positive data from the ProstACT SELECT trial of TLX591. TLX591 is an investigational anti-PSMA1 radio-antibody-drug conjugate (rADC) therapy being developed for the treatment of mCRPC, differentiated by a short two-week dosing regimen. Shares are trading 7.81 per cent higher at $16.97.
Telix Pharmicals（澳大利亚证券交易所股票代码：TLX）宣布了来自 TLX591 Prostact SELECT 试验的更多阳性数据。TLX591 是一种正在研发的抗PSMA1放射性抗体药物偶联物（RadC）疗法，用于治疗mcRPC，其区别在于短短的两周给药方案。股价上涨7.81％，至16.97美元。
AVITA Medical (ASX:AVH) announces FDA approval of RECELL GO. The RECELL GO System is a cell harvesting device that harnesses the regenerative properties of a patient's own skin to treat thermal burn wounds and full-thickness skin defects. Shares are trading 12.78 per cent higher at $3.00.
AVITA Medical（澳大利亚证券交易所股票代码：AVH）宣布美国食品药品管理局批准RECELL GO。RECELL GO 系统是一种细胞收集设备，它利用患者自身皮肤的再生特性来治疗热烧伤口和全层皮肤缺陷。股价上涨12.78％，至3.00美元。
EZZ Life Science (ASX:EZZ) has signed a five-year sales agreement with Pinehills (Hong Kong). Pinehills has committed to purchasing EZZ-branded products with a minimum value of A$15m in the first 12-months. Shares are trading 3.06 per cent higher at $1.01.
EZZ Life Science（澳大利亚证券交易所股票代码：EZZ）已与Pinehills（香港）签署了为期五年的销售协议。Pinehills已承诺在最初的12个月内购买最低价值为1500万澳元的EZZ品牌产品。股价上涨3.06％，至1.01美元。
